Th17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis by unknown
RESEARCH Open Access
Th17-skewed immune response and cluster
of differentiation 40 ligand expression in
canine steroid-responsive meningitis-
arteritis, a large animal model for
neutrophilic meningitis
Jessica Freundt-Revilla1,6*, Arianna Maiolini1, Regina Carlson1, Martin Beyerbach2, Kai Rentmeister3, Thomas Flegel4,
Andrea Fischer5 and Andrea Tipold1,6
Abstract
Background: Steroid-responsive meningitis-arteritis (SRMA) is an immune-mediated disorder characterized by
neutrophilic pleocytosis and an arteritis particularly in the cervical leptomeninges. Previous studies of the disease
have shown increased levels of IL-6 and TGF-ß1 in cerebrospinal fluid (CSF). In the presence of these cytokines,
naive CD4+ cells differentiate into Th17 lymphocytes which synthesize interleukin 17 (IL-17). It has been shown that
IL-17 plays an active role in autoimmune diseases, it induces and mediates inflammatory responses and has an
important role in recruitment of neutrophils. The hypothesis of a Th17-skewed immune response in SRMA should
be supported by evaluating IL-17 and CD40L, inducing the vasculitis.
Methods: An enzyme-linked immunosorbent assay (ELISA) was performed to measure IL-17 and CD40L in serum
and CSF from a total of 79 dogs. Measurements of patients suffering from SRMA in the acute state (SRMA A) were
compared with levels of patients under treatment with steroids (SRMA T), recurrence of the disease (SRMA R), other
neurological disorders, and healthy dogs, using the two-part test. Additionally, secretion of IL-17 and interferon
gamma (IFN-γ) from the peripheral blood mononuclear cells (PBMCs) was confirmed by an enzyme-linked
immunospot (ELISpot) assay.
Results: Significant higher levels of IL-17 were found in CSF of dogs with SRMA A compared with SRMA T, other
neurological disorders and healthy dogs (p < 0.0001). In addition, levels of CD40L in CSF in dogs with SRMA A and
SRMA R were significantly higher than in those with SRMA T (p = 0.0004) and healthy controls (p = 0.014). Furthermore,
CSF concentrations of IL-17 and CD40L showed a strong positive correlation among each other (rSpear = 0.6601;
p < 0.0001) and with the degree of pleocytosis (rSpear = 0.8842; p < 0.0001 and rSpear = 0.6649; p < 0.0001, respectively).
IL-17 synthesis from PBMCs in SRMA patients was confirmed; however, IL-17 is mainly intrathecally produced.
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Conclusions: These results imply that Th17 cells are inducing the autoimmune response in SRMA and are involved in the
severe neutrophilic pleocytosis and disruption of the blood-brain barrier (BBB). CD-40L intrathecal synthesis might be
involved in the striking vasculitis. The investigation of the role of IL-17 in SRMA might elucidate important
pathomechanism and open new therapeutic strategies.
Keywords: Steroid-responsive meningitis-arteritis (SRMA), Interleukin-17 (IL-17), Cluster of differentiation 40 ligand (CD40L),
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Background
Steroid-responsive meningitis-arteritis (SRMA) is the
most frequently diagnosed meningitis in canines [1]. It is
a systemic immune-mediated disorder [2] characterized
by systemic inflammatory lesions of the vessels, but
particularly in the cervical leptomeninges [3, 4] and in a
recognized large animal model for neutrophilic meningi-
tis [5]. This disorder affects typically young adult dogs
[6], can occur in any breed, although beagles, boxers,
Bernese mountain dogs [3, 7], Weimaraners, Nova Scotia
duck tolling retrievers [2], and Petit Basset Griffon Vendéen
[8] are over-represented.
Two different forms of SRMA are recognized, a typical
acute form and a protracted atypical form [7]. In the acute
one, common clinical signs include fever, reluctance to
move, stiff gait, cervical rigidity, and pain [3]; the analysis
of cerebrospinal fluid (CSF) reveals a marked poly-
morphonuclear pleocytosis and elevated protein [7]. The
protracted form may be observed following relapses and
neurological deficits like reduced menace response,
anisocoria, strabismus, and variable degrees of paresis and
ataxia might occur; CSF analysis at this stage reveals
mononuclear or mixed cell populations [7].
The etiology of SRMA remains unknown, even a genetic
predisposition was described in Nova Scotia duck tolling
retrievers [9]. Up to now, no infectious agents eliciting the
disease have been consistently detected [4, 6, 7, 10–12].
Several studies [13–17] confirmed an immune-mediated
disease. Furthermore, high concentrations of immuno-
globulin A (IgA) have been found both intrathecally and
systemically in dogs affected with SRMA [13, 18].
A predominance of T helper lymphocytes (CD4+) in the
peripheral blood [15] with a prominent Th2-mediated
immune response in dogs suffering from SRMA was
shown [17]. Furthermore, increased levels of interleukin 6
(IL-6) and transforming growth factor beta 1 (TGF-ß1)
have been found in CSF. A combined intrathecal increase
of these proteins could induce CD4+ progenitors to
differentiate to the recently discovered third T helper
subset (Th17) and enhance the autoimmune response in
SRMA [14].
Interleukin 17 (IL-17) synthesizing cells are known to
be involved in the pathogenesis of several autoimmune
diseases [19–22]. IL-17 is a pro-inflammatory cytokine
secreted primarily not only by activated T cells [23] but
also by neutrophils [24], eosinophils [25], and mono-
cytes [26] and acts on the IL-17 receptor (IL-17R)
[27]. Furthermore, IL-17 has a role, coordinating local
tissue inflammation through the induced release of
pro-inflammatory and neutrophil-mobilizing cytokines
[28, 29]. It has been shown to disrupt tight junctions
between the endothelial cells of the blood-brain
barrier in humans [30]. These mechanisms might
explain an influence of IL 17 on the massive invasion
of neutrophils into the subarachnoidal space in dogs
affected with SRMA.
The CD40 Ligand or CD154 is primarily expressed on
the surface of activated CD4+ T cells [31]. However,
activated T cells not only express CD40L on their
membranes, but a soluble, biologically active form of
CD40L also interacts with the CD40 receptor [32]
expressed mainly by B cells but also by many other cells
[31]. The vascular endothelial cells express the CD40
receptor, and its interaction with CD40L leads to endo-
thelial cell activation and leukocyte adhesion [33].
In the current study, we hypothesized the following:
(1) that a Th17-skewed immune response is involved in
the inflammatory reaction in SRMA and should be
confirmed by evaluating IL-17 systemically, intrathecally,
and at the cellular level; (2) that a dysregulated expres-
sion of CD40L is presumably involved in the pathogen-
esis of SRMA. Upon confirmation of a Th17-skewed
immune response, new treatment strategies directly
influencing this cell population could be evaluated in
this model.
Methods
Serum and cerebrospinal fluid samples
Ninety-eight serum and 98 CSF samples were collected
between 2005 and 2015, aliquoted and stored at −20 °C
until determination of IL-17 and CD40L concentrations
by a sandwich enzyme-linked immunosorbent assay
(ELISA) was performed. Samples were taken from
client-owned patients and controls derived from healthy
university-owned beagles of the University of Veterinary
Medicine Hannover, Germany. This study was con-
ducted in accordance with the ethical guidelines of the
University of Veterinary Medicine Hannover and was
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approved by the authorities of Lower Saxony (Animal
experiment number 33.9-42502-05-14A453). CSF sam-
ples were collected by suboccipital puncture of the dogs
under general anaesthesia, and serum samples were
obtained by puncture of the cephalic or saphenous
peripheral vein. All control dogs had routine CSF pa-
rameters in physiological ranges relating to the cell
count (0–3 cells/μl), glucose (60–80% of the blood glu-
cose concentration), and protein (less than 25 mg/dl)
[34]. CSF samples with severe blood contamination were
excluded, and in ten inflammatory CSF samples, a
slightly elevated erythrocyte count was detected reflect-
ing the vasculitis in SRMA [35]. Clinical and neurological
examinations in all the healthy control dogs revealed no
pathological findings. Client-owned patients were divided
into four groups: SRMA in the acute stage (SRMA A),
SRMA showing relapses of the disease (SRMA R), SRMA
under treatment with glucocorticosteroids (SRMA T), and
miscellaneous (neoplasia, intervertebral disc herniation
(IVDH), fever of unknown origin, and meningoencephal-
itis of unknown origin (MUO).
SRMA in the acute stage was defined by occurrence
of cervical rigidity and pain, fever, and polymorpho-
nuclear pleocytosis in the CSF. IgA content in serum
and CSF was determined to support diagnosis of
SRMA as previously described [7]. Other possible
causes of neck pain, elevated body temperature and/
or pleocytosis were ruled out. Patients in the SRMA
A group were not pre-treated with glucocorticoster-
oids prior to CSF puncture. Clinical signs, previous/
ongoing treatment and CSF parameters for the three
stages of the disease (SRMA acute, SRMA relapse
and SRMA under treatment) at the time of sampling
were considered as previously described [14].
EDTA blood samples
Fresh ethylenediaminetetraacetic acid (EDTA) blood
samples were prospectively collected from 18 healthy
university-owned beagles and 96 client-owned patients
suffering from different neurological disorders
between 2014 and 2015 at the Department of Small
Animal Medicine and Surgery, University of Veterin-
ary Medicine Hannover, Germany. The diagnosis of
the neurological disorder was performed by a resident
or a diplomate of the European College of Veterinary
Neurology (ECVN). Diagnoses were based on clinical
signs, neurological examination, complete blood cell
count, blood chemistry, CSF analysis, different im-
aging techniques, electrophysiology, surgery, and/or
histopathology when needed. EDTA blood was imme-
diately processed after sampling for isolation of the
peripheral blood mononuclear cells (PBMCs), which
were subsequently used for the ELISpot assays.
PBMCs isolation and freezing
The mononuclear cell fraction was separated by density
gradient centrifugation, using Histopaque®-1.199 (N°
11191, Sigma-Aldrich®, Saint Louis, USA) and Pancoll
human 1.077 (N° P04-60500, Pan Biotec™) as described
before [36]. Isolated PBMCs were washed three times
with phosphate-buffered saline (PBS buffer: 8.00 g NaCl,
0.20 g KCl, 1.15 g Na2HPO4, 0.20 g KH2PO4, in 1000-ml
ultrapure water, pH 7.4). When the cell pellet was
contaminated with erythrocytes, hypotonic lysis was
performed using purified water and double-concentrated
PBS. Subsequently, the number of viable cells was
determined by staining with Tryptan blue solution 0.4%
(N° T6146, Sigma-Aldrich®, Saint Louis, USA) in PBS.
The cells were resuspended and diluted to a concentra-
tion of 40 × 106 cells/ml in an ice-cold Roswell Park
Memorial Institute 1640 medium with L-glutamine phe-
nol red (RPMI 1640 Medium, 21875-034, Gibco®) and
15% serum replacement-1 (S0638, Sigma-Aldrich®, Saint
Louis, USA). The following steps were performed on ice:
0.5 ml of cell suspension was dispensed in labelled cryo-
vials and ice-cold RPMI 1640 medium with L-glutamine,
15% serum replacement-1, and 20% dimethyl sulfoxide
(DMSO, Sigma-Aldrich®, Saint Louis, USA) was added
slowly to obtain a final cell suspension of 20 × 106 cells/
ml. Finally, the cryovials were placed immediately in a
freezing container (N°5100-0001, Fisher Scientific
GmbH, Schwerte, Germany) and stored at −90 °C. After
>24 h the cryovials containing the cell suspension were
stored at −150 °C until further analysis.
Determination of IL-17 and CD40L concentrations in CSF
and serum
Both proteins were measured in CSF and serum samples
using sandwich enzyme-linked immunosorbent assay
commercial kits to detect canine IL-17 (SEA063Ca,
Cloud-Clone Corp., Houston, USA) and canine CD40L
(SEA119Ca, Cloud-Clone Corp., Houston, USA), follow-
ing the manufacturer’s protocols. Briefly, CSF, serum
samples, and standards of the tested proteins were di-
luted to the desired dilutions. Samples were diluted in
0.01 mol/L PBS, pH 7.0–7.2. Final dilution for most
SRMA A and SRMA R samples was of 1:8 for IL-17 in
CSF as most of these samples exceeded the maximal de-
tectable value. Standard or samples were added in dupli-
cates (100 μl per well) in 96-well pre-coated plates and
incubated for 2 h at 37 °C. Subsequently, the liquid of
each well was removed followed by incubation with
100 μl per well of detection agent A (biotin-conjugated
antibody specific to canine IL-17 or canine CD-40L) for
1 hour at 37 °C. After washing three times, the
remaining wash buffer was removed by decanting and
100 μl per well of detection agent B (avidin conjugated
to horseradish peroxidase) were added to each well and
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incubated for 30 min at 37 °C. After adequate washing
steps, 90-μl/well TMB chromogenic substrate (3.3′.5.5′
Tetramethylbenzidine) was added and incubated for
25 min at 37 °C. After adding 50-μl stop solution con-
taining sulphuric acid, the plates were measured using a
microplate reader (Synergy 2 Multi-mode microplate
reader, BioTek Instruments Inc., Bad Friedrichshall,
Germany) spectrophotometrically at a wavelength of
450 nm ± 10 nm.
All samples were tested in duplicates and the mean
value was calculated. The minimum detectable value for
IL-17 was 7.8 pg/ml and for CD40L 0.156 ng/ml, lower
values were considered negative (0 pg/ml and 0 ng/ml, re-
spectively). Samples resulting in measurements exceeding
the maximal detectable value for IL-17 (500 pg/ml) or
CD40L (10 ng/ml) were diluted and measured again.
Determination of IL-17 and IFN-γ-producing PBMCs
Quantitative determination of the frequency of PBMCs
releasing canine IL-17 and/or interferon gamma (IFN-γ)
was performed using a commercially available dual-
Color enzyme-linked immunoSpot (ELISpot) assay
(N° ELD6555, R&D Systems®, Inc., Minneapolis, USA),
following the manufacturer’s instructions. Briefly, all
reagents were brought to room temperature except for
the detection antibody concentrate and the dilution
buffer. Cells to be analysed were thawed and washed
with RPMI 1640 medium once the number of viable
cells was determined and two different dilutions were
made for each sample (2.5 × 105 cells/ml and 5 ×
105 cells/ml) in RPMI 1640 medium containing L-glu-
tamine, 15% serum replacement-1, and 4-μg/ml conca-
navalin A (N° C5275, Sigma-Aldrich®, St. Louis, USA)
for stimulation. Simultaneously, all wells from a 96-well
PVDF (polyvinylidine fluoride) membrane-backed mi-
croplate coated with a monoclonal antibody specific for
canine IFN-γ and a monoclonal antibody specific for
canine IL-17 were filled with 200-μl RPMI 1640 medium
containing L-glutamine and incubated for 20 min at
room temperature. When the cells were ready to be
plated, the medium of each well was removed and
100 μl of appropriate controls and PBMCs in stimulation
medium were added to each well. All samples and
controls were assayed in triplicate. The cells were stimu-
lated overnight at 37 °C in a 5% CO2 incubator. After
incubation, the wells were washed four times with wash
buffer (300 μl pro well) to remove the cells and culture
medium and 100-μl detection antibody mixture (con-
taining biotinylated polyclonal antibody specific for
canine IFN-γ and horseradish peroxidase-conjugated
polyclonal antibody specific for canine IL-17) was added
to each well and incubated at 4 °C overnight. After incu-
bation, the liquid of each well was removed by aspiration
and washing was performed four times with wash buffer.
One hundred microliter streptavidin-AP (streptavidin
conjugated to alkaline phosphatase) was added to each
well and incubated for 2 h at room temperature. After
adequate washing steps, 100 μl of BCIP/NBT chromogen
[5-bromo-4-chloro-3′indolylphosphate p-toluidine salt
(BCIP) and nitro blue tetrazolium chloride (NBT)] were
added to each well and incubated for 1 h protected from
light at room temperature. BCIP/NBT chromogen was
discarded and plates were rinsed once with deionized
water. After removal of water was completed, 100 μl
AEC (3-amino-9-ethylcarbazole) chromogen in stabiliz-
ing buffer (0.1% H2O2 in acetate buffer) were added to
each well incubating for 20 min protected from light at
room temperature. After decanting and rinsing with de-
ionized water, excess of water and plate underdrain were
removed. Finally, microplates were dried completely at
room temperature for 90 min before analysis.
An ELISpot puncher (Eli.Punch, A.EL.VIS GmbH,
Hannover, Germany) was used to remove the 96-well bot-
toms, and counting of spots was performed using an ELI-
Spot scanner and Analysis Software (Eli.Scan, A.EL.VIS
GmbH, Hannover, Germany). All samples were tested in
triplicates for both dilutions (2.5 × 105 cells/ml and 5 ×
105 cells/ml). Since the wells from the 5 × 105 cells/ml
dilution showed a high density of the spots and the 2.5 ×
105 cells/ml dilution showed better defined, distinct, sepa-
rated, clear spots, only this dilution was further analysed.
Red spots (IL-17-producing PBMCs) and black spots (IFN-
γ-producing PBMCs) were counted separately, and the
settings used were brightness: 75% and region of interest
(ROI): 66% (Fig. 1). Results are expressed in number of
spot-forming cells (SFC) per number of cells in each well.
Finally, the means from the well triplicates were calculated.
Statistical analysis
Statistical evaluation to test for significant differences of
IL-17 and CD40L concentrations in CSF and serum, and
IL-17- and IFN-γ-producing PBMCs, among the different
groups, was performed using SAS® software Version 9.3
(SAS Inst. Inc. Cary, NC, USA). Graphics from the statis-
tical data obtained were made by using GraphPad software
(GraphPad Prism®, version 5, La Jolla, CA, USA).
Statistical analysis of IL-17 and CD40L concentrations in
CSF and serum
In the statistical analyses, IL-17 and CD40L values under
the detection limits were treated like zeros and will be
referred to as “zero values” hereinafter. All groups were
compared pairwise using the two-part test [37, 38]. This
test combines the comparison of the percentages of
zeros using Fisher’s exact test and Wilcoxon’s two-
sample test of the values above the detection limits
(non-zero values). When not only zero values were
present in one or both groups but also values greater
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than zero in both groups, then the two-part test was
used. However, if there were only zeros in a group, only
the Fisher exact test was used. Furthermore, the two-
part test was not necessary for the analysis of CD40L in
serum, since no zeros were present in this variable.
Therefore, the Wilcoxon test alone was performed for
this analysis given that the non-zero values were not
normally distributed. Results are given as medians,
minimal and maximal values of the non-zero values, and
percentages of zero values. Additionally, Spearman’s
rank correlation coefficients (rSpear) were calculated
to determine correlations between IL-17 and CD40L
and between white blood cell count in CSF and both
proteins. A comparisonwise error rate of 5% was
applied in the analysis of the data, differences between
groups and correlation coefficients were claimed as
significant if the corresponding p values were lesser
than 0.05.
Given the prolonged period of storage of some serum
and CSF samples, linear regression analyses separated by
groups were performed to look for significant linear
regression coefficients of IL-17 and CD40L through the
years where the samples were collected. No significant
correlations between the concentration of the proteins
analysed and the years of sampling were found in any of
the groups (p > 0.05).
Statistical analysis of IL-17 and IFN-γ-producing PBMCs
Since these variables were not normally distributed
within the groups, all groups were compared pairwise
using the Wilcoxon two-sample test. Medians of the
means were compared and values of p < 0.05 were con-
sidered significant.
Results
Serum and CSF samples
Serum and/or CSF were collected and analysed from 79
dogs in total. In some dogs with SRMA, samples were
taken twice, in the acute phase (SRMA A) and during
treatment (SRMA T).
From the total of 98 CSF and serum samples, 89 were
paired CSF and serum samples. In some cases, both
proteins could not be measured because the material
was not sufficient (Table 1).
Among the patients with SRMA, 16 different breeds
and mixed-bred dogs were included. The most common
breeds were boxer (25%), Bernese mountain dogs (16.7%),
beagles (16.7%), and mixed breeds (10.4%). Most dogs
diagnosed with SRMA in the acute phase of the disease
were <1 year (55.2%), 34.48% were between 1- and 2-years
old, and 10.3% were between 2- and 3-years old.
Fig. 1 IL-17 and IFN-γ spot-forming cells. a Scan of a 96-well PVDF-backed ELISpot microplate. Positive and negative controls are shown vertically
in duplicates (A1-D3) and sample wells horizontally in triplicates (E1-H12). b Red spots (IL-17-producing PBMCs) and black spots (IFN-γ-producing
PBMCs) are presented in a zoomed well (C10). Brightness: 75% and region of interest (ROI): 66%
Table 1 Number of CSF and serum samples analysed for IL-17
and CD40L in each group
Groups IL-17 CD40L
CSF Serum CSF Serum
SRMA A 30 30 31 31
SRMA R 6 6 6 6
SRMA T 26 27 26 28
Healthy 12 14 14 14
Miscellaneous 8 9 8 8
Total 82 86 85 87
IL-17, interleukin-17, CD40L cluster of differentiation 40 ligand, CSF cerebrospinal fluid,
SRM A steroid-responsive meningitis-arteritis in acute stage, SRMA R recurrence of
SRMA, SRMA T SRMA patients under treatment
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CSF and serum concentrations of IL-17
The highest concentrations of IL-17 were found in CSF
samples of patients with SRMA A (median 901.77 pg/mL;
range 70.73–2967.14 pg/mL; percentage of zeros 0%),
followed by those with SRMA R (median 533.01 pg/mL;
range 97.52–1771.87; percentage of zeros 0%). Concentra-
tions of IL-17 CSF samples “SRMA A” differed signifi-
cantly from other groups, SRMA T (p < 0.0001), healthy
dogs (p < 0.0001), and miscellaneous (p = 0.0005).
However, there was no difference to values measured
in samples from dogs with relapses (SRMA R), a
group also displaying significant differences with
SRMA T (p = 0.0004), healthy dogs (p = 0.0051), and
miscellaneous (p = 0.0415).
Similarly, the highest values of IL-17 in serum were
found in dogs with SRMA A (median 45.95 pg/mL;
range 12.18–251.53 pg/mL; percentage of zeros 50%),
followed by serum samples of dogs with SRMA R (me-
dian 43.30 pg/mL; range 12.52–126.74 pg/mL; percent-
age of zeros 16.67%). Significantly higher values were
found in SRMA A when compared with the group “mis-
cellaneous” (p = 0.0445). Furthermore, statistically
significant differences were found between the groups
“SRMA R” and “healthy” (median 32.34 pg/mL; range
9.40–87.46 pg/mL; percentage of zeros 14.29%) when
compared with SRMA T (p = 0.0166 and p = 0.0021,
respectively) and miscellaneous (p = 0.0268 and p =
0.0022, respectively).
IL-17 concentrations in CSF and serum, in addition to
percentage of zeros (values under the detection limits),
are summarized in Table 2. Significant differences
among groups are shown in Fig. 2.
CSF and serum concentrations of CD40L
CD40L concentrations in CSF were overall very low; a
high number of values were found under the detection
limit. These values are described as “zero” values and are
expressed as percentage for each group.
The lowest values were found in the SRMA T group,
followed by the healthy group. Measurable CD40L con-
centrations and lower percentage of zeros were found in
the SRMA A and SRMA R groups. Statistically signifi-
cant differences occurred between the SRMA A (median
0.51 ng/mL; percentage of zeros 50%) and the SRMA R
(median 0.22 ng/mL; percentage of zeros 33.33%)
groups when compared with the SRMA T (p < 0.0001
and p = 0.0005, respectively) and healthy dogs (p =
0.0042 and p = 0.0145, respectively). CD40L concen-
trations in serum of all the groups examined did not
differ significantly, all values were above the detection
limit.
CD40L concentrations in CSF and serum as well as
the percentage of zeros are summarized in Table 2. Sig-
nificant differences among groups are displayed in Fig. 2.
Correlation analysis
CSF concentrations of IL-17 and CD40L showed a
strong positive correlation among each other (rSpear =
0.6601; p < 0.0001) and with the degree of pleocytosis in
all groups (rSpear = 0.8842; p < 0.0001 and rSpear =
Table 2 Concentrations of IL-17 and CD40L in CSF and serum samples analysed
Groups IL-17 (pg/mL) CD40L (ng/mL)
CSF Serum CSF Serum
SRMA A Median 901.77 45.95 0.51 1.37
Range (70.73–2967.14) (12.18–251.53) (0.16–1.95) (0.25–3.10)
Percentage of zeros 0% 50% 50% –
SRMA R Median 533.01 43.30 0.22 1.37
Range (97.52–1771.87) (12.52–126.74) (0.17–0.91) (0.76–3.06)
Percentage of zeros 0% 16.67% 33.33% –
SRMA T Median 29.67 21.04 0 1.29
Range (12.47–78.86) (8.10–32.92) (0–0) (0.29–6.39)
Percentage of zeros 38.46% 59.26% 100% –
Healthy Median 30.90 32.34 0.17 1.70
Range (15.45–172.17) (9.40–87.46) (0.17–0.17) (0.38–5.75)
Percentage of zeros 8.33% 14.29% 92.86% –
Miscellaneous Median 53.54 10.98 0.63 1.08
Range (13.64–221.82) (8.65–13.30) (0.63–0.63) (0.48–5.80)
Percentage of zeros 30% 69.23% 72.73% –
Median and range (minimum-maximum) of values above the detection limits and percentage of zeros for each group
IL-17 interleukin-17, CD40L cluster of differentiation 40 ligand, CSF cerebrospinal fluid, SRMA A steroid-responsive meningitis-arteritis in acute stage, SRMA R
recurrence of SRMA, SRMA T SRMA patients under treatment
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0.6649; p < 0.0001, respectively). In SRMA A and SRMA
R, correlations between IL-17 levels in CSF and degree
of pleocytosis were rSpear = 0.7574 (p < 0.0001) and
rSpear = 0.8857 (p = 0.0188), respectively.
Blood samples for PBMCs used for determination of IL-17
and IFN-γ by ELISpot
After complete diagnostic workup was made, the
patients were divided in seven groups. The number of
PBMCs samples used for determination of IL-17 and
IFN-γ are shown in Table 3.
Number of PBMCs secreting IL-17 and IFN-γ
The lowest values were found in the healthy group (median
4.34 SFCs; range 0.67–14.00 SFCs), which differed signifi-
cantly from SRMA A (p = 0.0007), SRMA T (p= 0.0134),
idiopathic epilepsy (p= 0.0006), MUO (p= 0.0106), and
intervertebral disc herniation (IVDH) (p= 0.0266). The
number of IL-17-producing PBMCs in the epilepsy group
and in cases with MUO varied widely.
IFN-γ was mostly produced by PBMCs of the healthy
group (median 291.50 SFCs; range 77.67–695.00 SFCs).
Significant differences were found between this group
and all the other groups: SRMA A (p < 0.0001), SRMA T
Fig. 2 Concentration of IL-17 (a, b) and CD40L (c, d) in CSF and serum samples and percentage of zeros. Boxes contain values from the first to
the third quartile, lines inside the box indicate median values, endpoints of vertical lines represent minimum and maximum values, and • represent
outliners. Number sign represents percentage of zero values. Asterisks indicate statistically significant differences from the SRMA A group (****p <
0.0001, ***p < 0.005), plus indicate statistically significant differences from the SRMA R group (+++p < 0.005, ++p < 0.01, +p < 0.05) and circles indicate
statistically significant differences from the healthy group (oop< 0.01). IL-17: interleukin-17, CD40L: cluster of differentiation 40 ligand, CSF: cerebrospinal fluid,
SRMA: steroid-responsive meningitis-arteritis, SRMA A: acute stage of SRMA, SRMA R: recurrence of SRMA, SRMA T: SRMA patients under treatment
Table 3 Number of IL-17 and IFN-γ spot-forming cells (median
and range)
Groups IL-17 IFN-γ
SRMA A (n = 18) Median 12.83 43.83
Range (3.33–34.67) (1.67–315.00)
SRMA T (n = 9) Median 13.00 25.33
Range (1.00–95.33) (5.33–169.67)
Healthy (n = 16) Median 4.34 291.50
Range (0.67–14.00) (77.67–695.00)
Idiopathic epilepsy (n = 10) Median 28.33 109.17
Range (2.33–66.00) (35.33–350.00)
MUO (n = 8) Median 13.50 87.50
Range (3.33–74.67) (20.33–296.67)
IVDH (n = 7) Median 7.67 61.00
Range (5.67–44.67) (12.00–215.33)
Miscellaneous (n = 8) Median 6.84 42.50
Range (1.67–33.00) (14.00–369.00)
SFCs spot-forming cells, IL-17 interleukin-17, IFN-γ Interferon gamma, SRMA A
steroid-responsive meningitis-arteritis in acute stage, SRMA T SRMA patients
under treatment, MUO meningoencephalitis of unknown origin, IVDH intervertebral
disc herniation
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(p = 0.0005), idiopathic epilepsy (p = 0.0057), MUO (p =
0.0077), IVDH (p = 0.0029), and miscellaneous (p =
0.0053).
The number of IL-17 and IFN-γ SFCs are summarized
in Table 3. Significant differences between groups are
displayed in Fig. 3.
Discussion
In the current study, we could support the hypothesis
that SRMA is associated with a Th17-skewed immune
response. Increased intrathecal levels of IL-17 and
CD40L in patients with SRMA in the acute stage and
during relapses were detected. Furthermore, IL-17 CSF
levels showed a strong positive correlation with the
degree of pleocytosis (rSpear = 0.8842; p < 0.0001)
suggesting that IL17 might be involved in the massive
migration of neutrophils in the CSF and the induction of
vascular damage.
SRMA is a primary immune-mediated meningeal
disorder [3], but despite extensive research, the exact
etiopathogenesis remains unknown. The treatment of
choice are long-term glucocorticosteroids and when
dogs in the acute stage of the disease are treated
promptly, the prognosis is fair to good [2, 6]. Neverthe-
less, a recent study showed relapses in about 30% of the
cases where a lasting improvement is not achieved [39]
or the required dosage of glucocorticosteroids may lead
to severe side effects. Autoimmune diseases, both in
canines and humans, urge the development of new
treatment strategies with a specific mechanism of action
to avoid potentially serious side effects. In depth under-
standing and characterization of the cytokine profile
leading to a dysregulation of the immune system in
autoimmune inflammatory disorders allows implementa-
tion of novel therapeutic approaches based on specific
cytokine modulation. To date, no studies have been
performed on the recently discovered IL-17-producing
T cell subset (Th17) in SRMA patients. However, IL-17-
producing cells have an important role in the develop-
ment of several autoimmune diseases in humans such as
systemic lupus erythematosus [40], rheumatoid arthritis
[41], bronchial allergy [21], inflammatory bowel disease
[20], multiple sclerosis [42], and Kawasaki disease [43]
and also in experimental models such as collagen-
induced arthritis [19] and experimental autoimmune
encephalomyelitis (EAE) [22]. The extrapolation of find-
ings in experimental rodent models for human inflam-
matory diseases is very limited. SRMA as a naturally
occurring animal model for human meningitis and vas-
culitides of unknown origin including Kawasaki Syn-
drome [14, 15, 44, 45] might overcome this limitation.
Recently, IL-17-producing cells were found in inflamed
tissues of several chronic idiopathic disorders in dogs
including inflammatory bowel disease, gingivitis, chronic
idiopathic rhinitis, and chronic dermatoses [46]. Increased
levels of IL-17 were found in dog brain tissues with granu-
lomatous meningoencephalomyelitis (GME) [47]. Add-
itionally, in the current study, we could show increased
values of IL 17 and CD40L in serum and CSF of dogs with
SRMA, most probably having a role in the massive
invasion of neutrophils to the subarachnoidal space and
being involved in the development of the striking vasculitis.
IL-17 is upregulated both systemically and intra-
thecally in patients suffering from SMRA in the acute
phase and during relapses. IL-17 was measurable in all
CSF samples belonging to these two groups in contrast
to the control groups. Furthermore, most measurements
in CSF samples of SRMA A (median 901.77 pg/mL) and
SRMA R (median 533.01 pg/mL) groups exceeded the
maximal detectable value for IL-17 (500 pg/mL) of the
Fig. 3 IL-17 (a) and IFN-γ (b) spot-forming cells. Boxes contain values from the first to the third quartile, lines inside the box indicate median values,
and endpoints of vertical lines represent minimum and maximum values, and • represent outliners. Circles indicate statistically significant differences
from the healthy group (oooop < 0.0001, ooop < 0.005, oop < 0.01, op < 0.05). Number sign indicates statistically significant differences between idiopathic
epilepsy (#p < 0.05) and other groups. SFCs: spot-forming cells, IL-17: interleukin-17, IFN-γ: interferon gamma, SRMA A: steroid-responsive meningitis-
arteritis in acute stage, SRMA T: SRMA patients under treatment, MUO: meningoencephalitis of unknown origin, IVDH: intervertebral disc herniation
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ELISA kit and had to be diluted to obtain readable
values. Patients in the SRMA A and SRMA R groups
displayed a neutrophilic pleocytosis. In line with the
known ability of IL-17 to induce neutrophil recruitment
into sites of inflammation, the groups that displayed the
highest CSF IL-17 levels showed also the highest
numbers of neutrophils. Furthermore, the CSF concentra-
tions of IL-17 showed a strong positive correlation with
the degree of pleocytosis (rSpear = 0.8842; p < 0.0001).
Strikingly, IL-17 values measured in CSF exceeded 20
times the amount of IL-17 detected in the serum of pa-
tients in the SRMA A group and more than 10 times of
patients in the SRMA R group supporting the hypothesis
that IL17 is produced intrathecally and not a spill over
through a damaged blood-brain barrier. Although vascu-
lar lesions may be present in the coronary arteries and
other organs [45, 48, 49], the vasculitis in SRMA pa-
tients is accentuated in the subarachnoidal space of the
cervical meninges [7, 15]. All CSF samples in our pa-
tients were collected from the cisterna magna near to
the main lesions in SRMA. Circulating cytokines reach
high concentrations at the site of release, but after
dilution in the blood, much lower concentrations can be
found peripherally [50] as observed in the current study.
SRMA-affected dogs have higher number of helper
CD4+ T cells than cytotoxic CD8+ T cells in the periph-
eral blood [15]. This predominance of T helper (Th)
lymphocytes indicates that in SRMA patients a humoral
immune response is present, occurring typically to
eliminate extracellular pathogens or in autoimmune
diseases [15]. Naive CD4+ T cells differentiate into
different subsets with distinct effector functions when
activated in a specific cytokine environment [51].
Initially, Th differentiation was proposed to be divided
in two subpopulations based on their cytokine expres-
sion profiles: Th1 and Th2 [52]. Th1 synthesize IFN-γ
and mediate protection against intracellular pathogens
[51]. In former studies, this cytokine was only detected
in low levels in SRMA [17], we confirmed this finding in
the current study, demonstrating low IFN-γ spot-
forming cells in dogs with SRMA. Th2 cells synthesize
IL-4, IL-13, and IL-25, moderate the clearance of extra-
cellular pathogens [51], and were found to occur in
SRMA [17]. However, the paradigm of two Th subpopu-
lations was challenged following the discovery of a third
subset of Th cells, known as Th17 cells [53], which
synthesize IL-17 and are potent inducers of autoimmun-
ity and tissue inflammation [51]. Th17 cells require both
TGF-ß1 and IL-6 for their development [54, 55]. In
humans, IL-23 is essential for the maturation of inflam-
matory Th17 cells [22]. It has been shown that IL-6-
deficient mice fail to develop a Th17 response and are
resistant to the development of EAE [55, 56] and
collagen-induced arthritis [57]. In recent studies,
increased levels of IL-6 and TGF-ß1 were described in
CSF of canines suffering from SRMA. A combined intra-
thecal increase of these proteins could induce CD4+
progenitors to differentiate into Th17 subset and en-
hance the autoimmune response [14]. Additionally, den-
dritic cells activated by Toll-like receptor (TLR) 4 and
TLR9, produce IL-23, which subsequently can activate
CD4+ T cells shifting towards Th17 differentiation under
the effect of IL-6 and TGF-ß1 [5]. In SRMA, such an in-
fluence of Toll-like receptors was already shown [5] and
furthermore supports the hypothesis of a Th17-skewed
immune response in the described disease.
IL-17 has been designated IL-17A to indicate that it is
the founding member of the IL-17 cytokine family con-
sisting of IL-17A-F members [27, 58] playing an active
role in inflammatory responses and in autoimmune dis-
eases [29]. IL-17 is a pro-inflammatory cytokine secreted
primarily by activated T cells [23, 24, 29, 30, 58, 59],
although it is also produced by neutrophils [24], eosino-
phils [25], and monocytes [26]. IL-17 acts on the IL-17
receptor (IL-17R) expressed on the cells of all the tissues
examined to date [27]. The activation of IL-17R results
generally in the induction of other pro-inflammatory cyto-
kines [27]. IL-17 induces the release of IL-6 and other cyto-
kines that trigger an inflammatory reaction characterized by
neutrophil influx [21] and promotes granulopoiesis [28].
Experimental studies showed that overexpression of IL-17 in
the joint space of mice with collagen-induced arthritis leads
to increased neutrophil recruitment [60]. Interestingly, the
mechanisms by which IL-17 disrupts the tight junctions be-
tween the endothelial cells of the blood-brain barrier (BBB)
were recently demonstrated and the ability of Th17 cells to
transmigrate efficiently across the BBB was proven [30].
Expression of IL-17 and IL-22 receptors on the endothelial
cells of the BBB results in the binding of Th17 cells to the
BBB tight junctions which causes its disruption and allows
Th17 cells to transmigrate across the BBB [61]. Further-
more, IL-17 enhances inflammatory cytokine production by
microglia and even its synthesis by microglia and astrocytes
has been proven [62]. Altogether, these mechanisms might
explain the striking increase of IL-17 intrathecally and its
influence on the massive invasion of neutrophils into the
subarachnoidal space in dogs affected with SRMA.
Patients in the SRMA T group were under long-term
treatment with prednisolone as previously described [35]
and did not show any clinical signs at the time of sam-
pling and had CSF parameters in physiological ranges.
IL-17 levels in these patients were both low in CSF (me-
dian 29.67 pg/mL) and in serum (median 21.04 pg/mL).
Glucocorticoids are known to induce lymphocyte
apoptosis and alter leukocyte migration and redistribu-
tion. The most important immunosuppressive effect of
glucocorticosteroids is on T cell activation by inhibition
of the genes that encode for cytokine production [63].
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The mechanisms of action of glucocorticoids are, how-
ever, unspecific and are associated with potentially ser-
ious side effects [63, 64]. In SRMA, management of the
clinical signs and a complete remission is often achieved
with long-term treatment with prednisolone [2]. In re-
fractory cases, other immunosuppressive drugs are used
in combination with glucocorticoids [2, 39]. However, in
approximately 30% of the patients a lasting improvement
is not achieved, relapses are persistent [39], and un-
acceptable side effects appear [64]. In humans, up to
30% of patients treated for inflammatory diseases de-
velop glucocorticoid resistance [64]. Hence, novel thera-
peutic strategies targeting specific aspects of the
immune response are practiced in human medicine.
Current medical trials aimed to neutralize IL-17 or IL-
23 have shown to be highly effective in humans in the
treatment of psoriasis and show promising initial results
in ankylosing spondylitis and multiple sclerosis [65].
These innovating therapies are now appearing in com-
panion animal medicine [66] and should be considered
in inflammatory autoimmune diseases like SRMA.
In the second part of our study, increased levels of sol-
uble CD40L in CSF of dogs with SRMA A (median 0.51;
range 0.16–1.95 ng/mL) and SRMA R (median 0.22;
range 0.17–0.91 ng/mL) were found when compared
with all other groups. Interestingly, CD40L was not
measurable in any CSF sample of the SRMA T group
and only in one sample of the healthy (0.17 ng/mL) and
one of the miscellaneous (0.67 ng/mL in meningo-
encephalitis of unknown origin) groups. To our know-
ledge, serum and CSF values of CD40L have not been
previously evaluated in canines, and hence no reference
values have been established. It was unexpected to find
no differences in the expression of CD40L in serum
among any of the groups.
The CD40 ligand or CD154 is a transmembrane glyco-
protein from the tumor necrosis factor α (TNF α) family
primarily expressed on the surface of activated CD4+ T
cells which interacts with the CD40 receptor expressed
principally in B cells but also in other cells [31]. Acti-
vated T cells not only express CD40L in their mem-
branes but also produce a soluble form of CD40L, which
is biologically active and interacts also with the CD40
receptor [32]. The CD40 receptor is expressed by the
vascular endothelial cells and its activation by CD40L
leads to leukocyte adhesion [33].
Our results showed increased levels of CD40L in
CSF in dogs in the acute stage and during relapses of
SRMA. High levels of soluble CD40L can regulate
CNS inflammation at the BBB [67]. Recently, in-
creased expression of CD40L in CD4+ T cells as well as
soluble CD40L was found in patients with Kawasaki
disease and the levels correlated with coronary artery
lesions [68].
The third part of our study aimed to confirm IL-17 se-
cretion by PBMCs at the single cellular level by ELISpot
assays. The development of novel tools allows us to
study cell-mediated immunity in a more sensitive and
precise manner. Since its development in 1983 [69], the
ELISpot assays have been employed in the identification
of cytokine-producing cells at the single-cell level allow-
ing the visualization and quantification of the secretory
products of individually activated cells. The dual ELISpot
allows simultaneous detection of two cytokines. We
performed ELISpot assays to detect IL-17 (indicating a
Th17 response) and IFN-γ (indicating a Th1 response)
in PBMCs after cryopreservation. Previous studies in
humans have shown full functionality after cryopreserva-
tion of PBMCs [70]. Our results proved IL-17 and IFN-γ
production of activated and responsive PBMCs after
cryopreservation in canines. IL-17 is produced by
PBMCs and not only by neutrophils occurring in high
numbers in CSF samples of dogs with SRMA.
Given the systemic nature of SRMA [17, 71], PBMCs
were isolated and IL-17 production was evaluated at a
single-cell level by an ELISpot assay. Although, a higher
number of IL-17 SFCs were found in the SRMA A group
than in the healthy group, an increased production of
IL-17 in PBMCs was also found in all the other groups
when compared with the healthy controls. Intriguingly,
single patients of the group with idiopathic epilepsy
showed more spot-forming cells as found in all other
diseases. Interictal increased levels of IL-17 in CSF and
serum have been found in humans with three types of
epilepsy (temporal lobe epilepsy, extra-temporal lobe
epilepsy, and idiopathic generalized epilepsy) [72]. An-
other group found a significant correlation among in-
creased IL-17 levels and seizure frequency, IL-17 is
known to facilitate Th17 migration across the BBB [73].
Another explanation could be the presence of single
cases with immune-mediated diseases among our idio-
pathic epilepsy group. In humans, some seizure disor-
ders once thought to be idiopathic now seem to be
immune-mediated [74] and occurrence of autoantibodies
to different neuronal structures were found [74–76].
Nonetheless, we have clearly demonstrated the IL-17
production at the single-cell level in the peripheral blood
in SRMA patients and compared it to positive and nega-
tive controls.
Finally, IFN-γ spot-forming cells in SRMA patients in
the acute as well as those under treatment remained
low. Previous studies demonstrated a downregulation of
IFN-γ mRNA expression by means of reverse transcript-
ase real-time polymerase chain reaction in dogs with
SRMA in the acute phase [17]; our findings confirmed
low IFN-γ expression at the protein level compared to
healthy dogs excluding a Th1 response and further
supporting a Th17 response.
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The current study is, to our knowledge, the first one
to demonstrate IL-17 expression in canine CSF and its
involvement in the pathogenesis in SRMA patients. Our
findings follow up the already known roles of cytokines
involved in the pathogenesis of SRMA [77] and give a
clear direction for future treatment approaches.
Conclusions
The described results imply that Th17 cells are inducing
the autoimmune response in SRMA and are involved in
the development of the severe neutrophilic pleocytosis
and disruption of the BBB. The investigation of the role
of IL-17 and CD40L in SRMA adds to the knowledge of
pathophysiological mechanisms in SRMA and opens the
discussion about new therapeutic strategies in this valu-
able naturally occurring large animal model.
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